Sanofi said the GEMINI 1 and 2 trials of tolebrutinib in relapsing forms of MS are fully enrolled and should read out in time to meet its plan of filing for regulatory approval in the US in 2024.
In that trial, the Sanofi drug candidate slowed disability progression when compared with a placebo, an ineffective dummy drug. "Tolebrutinib represents an unprecedented breakthrough as a ...
Some results have been hidden because they may be inaccessible to you